Home
-
Pharma & Tariffs: US Supreme Court Weighs In
The US Supreme Court heard oral arguments in cases involving the legality of reciprocal tariffs, country-by-country tariffs imposed through a series of trade deals and executive actions. Is tariff relief a possibility or not?
-
The Next Wave of Biologics: What’s Trending
Which biologics have received approval by FDA’s Center for Drug Evaluation and Research thus far in 2025, and how are they positioned in the market? What other market contenders loom in the industry’s pipeline?
-
The Battle in the Obesity Drug Market Heats Up
Novo Nordisk’s bid to best a previous offer from Pfizer to acquire the bio/pharma company, Metsera, is the latest in the competitive obesity drug market. What are the assets the companies are vying for, and how do they stack up against other contenders in the obesity drug market?
DCAT MEMBER COMPANY COMMUNITY
-
New DCAT Member Company Alert
Welcome to our Newest Member Companies! We are pleased to welcome the following companies to our DCAT Member Community. To View all DCAT member companies visit the Member Directory. From the…
-
ESG Update: DCAT Member Companies in the Community
The latest ESG (environmental, social and governance) news from DCAT Member Companies on how they are making an impact globally and in their local communities. Have a ESG news announcement…
-
ICYMI: Production to Prescription Podcast: Drug Launches & Approvals in 2025: The Blockbuster Contenders
Each year, the promise of new market entries loom in the bio/pharmaceutical industry. Which products, launched or approved thus far in 2025, may be potential blockbusters (defined as drugs with sales of $1…
-
Unwind and Network With Us at DCAT After the Show in Frankfurt
Are you attending the show in Frankfurt? Don’t miss DCAT After the Show on Wednesday, October 29, at 7:00 – 9:30 PM, an exclusive networking experience for employees of DCAT Member Companies. After a busy…
